A robust, cross-functional approach to set the strategic direction for pipeline assets and their target indications in the context of an existing portfolio.
Supporting pharma companies to adapt for a changing healthcare landscape
Healthcare ecosystems around the world are being revolutionized by new therapies, yet provider capacity is distressed, regulator and payor models are under strain, and patient expectations are growing and evolving.
These external shifts accelerate pharma companies’ urgent need to drive efficiency into development and to adapt go-to-market strategies and operating models to become more customer-focused and agile.
Where pharma executives engage management consulting support to help work through these topics, it should be expertise-led and outcome-driven.
Lucid Strategy Consulting offers a distinctive approach.
Ready to amplify the value of your medicines?
Ready to amplify the value of your medicines?
What we’ll unlock together
We are a strategic management consulting firm dedicated to life sciences, helping our pharma clients in three main areas:
Asset Strategy:
We help life sciences leaders define ans execute integrated strategies that enhance asset and portfolio value, optimise lifecycle performance and align commercialisation strategy and planning with actionable solutions.
Business Design & Transformation:
We drive organizational improvements, notably the re-invention of market-facing functions such as Medical Affairs and Commercial, to adapt to significant shifts in the healthcare sector worldwide.
Innovative strategies demand adaptation of historic operating models and roles, especially harnessing the power of data & AI.
Patient & Customer Value:
We increase our clients' competitive advantage by enabling them to deliver patient and HCP customer experiences that improve outcomes.
Our work improves organizational performance across the value chain - ensuring functions truly prioritze stakeholder needs in ways that improve their preference, loyalty, and advocacy, as well as patient outcomes.
Explore our core Strategy Consulting capabilities
Pharma companies are facing ever-lasting complexity in the development lifecycle, not least working across clinical/medical, commercial, regulatory, data, technical and operational disciplines. And bringing commercial and real-world thinking earlier into the lifecycle is becoming imperative for market entry.
What we do
- Market, asset and portfolio evaluation
- Early asset strategy and value propositions
- Launch excellence strategy and planning
- Asset and Portfolio lifecycle strategy
- Integrated strategic planning, including strategic brand planning, IEGP, and lifecycle management
Our clients tell us they most value our help in accelerating time-to-approval, richer engagement with KOLs and other stakeholders at the right moments along the journey, as well as our experience spanning the largest pharma multi-indication assets through to first-launch biotech assets.
View case studies
Every pharma company faces a set of complex and multi-faceted challenges to refine strategies, go-to-market, operating and organizational models, driven by changing market conditions and the need to continuously improve performance. When expert, external help is needed, we bring insight and solutions in: - Future-fit operating model strategy, design & implementation - Agile organization design & implementation - Process design & optimization - Program, business case, stakeholder & change management - Market landscape & partner selection - Data & technology architectures & solutions - AI strategy, governance, use case definition, build & adoption.
Where we are different is that we are big enough but not too big, we are all highly experienced consultants who know how to embrace AI in consulting projects, and deep insight into the subtle but critical issues pharma faces today is far ahead of generalist management consulting firms. Our clients tell us we are easy to partner with, and we target measurable and rapid outcomes.
View case studies
- Design of Global Medical Affairs Operating Model
- Establishing a Digital, Data & Analytics (DDA) Group for Global Medical Affairs
- Leadership Team Strategic Vision & Culture for Global Head of Development
- Transforming the R&D Operating Model at a Specialty Biopharma
- Launching a Transformation Program for Global Medical Affairs Oncology
Every pharma company is facing Increasing competition as well as challenges in accessing customers and patients. Legacy internal and product focused ways of working are reaching the end of their effectiveness. To be competitive in securing preference, companies need to be able to deliver experiences and outcomes that customers and patients really need.
What we do
- We enable clients to adopt leading customer and patient experience management practices, aligning their organizations to collaboratively prioritize creation of stakeholder preference, loyalty and advocacy.
- From designing experiences, building solutions and functions to deliver them, through to measuring, optimizing and improving ROI –we support clients by making customer and patient experiences a driver of growth through industry leading advice and project delivery.
Clients engage us because they value how we combine leading practices with deep industry experience to provide practical support that delivers real and measurable outcomes.
View case studies
Are you ready to drive sustainable transformation in your organisation?
Are you ready to drive sustainable transformation in your organisation?
Explore our capabilities
Explore how our core capabilities, enabled by AI and advanced analytics, work together to drive belief, accelerate adoption, and create the momentum your brand needs to lead.
Explore our Strategy Consulting case studies
Explore our Strategy Consulting case studies
Global evidence generation strategy
Global evidence generation strategy
Development of an evidence-generation strategy and expanded LCM opportunities to drive competitive differentiation aligned to stakeholder market-value drivers.
See case study
Portfolio buy and build
Portfolio buy and build
A thorough process to assess and validate future development and acquisition targets, optimising portfolio and disease area strategy and aligning key stakeholders to plan.
See case study
Outsourcing strategy for scalable growth
Outsourcing strategy for scalable growth
Target Clinical Development outsourcing operating model.
See case study
Digitising Medical planning
Digitising Medical planning
Digitising of Global oncology Medical strategy plans across assets.
See case study
Accelerating the pathway to launch for a breakthrough oncology asset
Accelerating the pathway to launch for a breakthrough oncology asset
Our client needed a partner to help them navigate the journey to launch and successfully bring their product to market while creating a model for future launches across the organisation.
See case study
Explore our Strategy Consulting white papers
Explore our Strategy Consulting white papers
DCTs: achieving our ambition
DCTs: achieving our ambition
Decentralised clinical trials (DCTs) present a biopharmaceutical company with a series of opportunities and challenges. We highlight the challenges and examine...
See article and view paper
Medical operations of the future
Medical operations of the future
As Medical Affairs organisations continue to evolve, the 'Medical Operations' or 'Medical Excellence' group is becoming increasingly important. This paper explores how Medical Operations groups can best evolve to...
See article and view paper
Medical Affairs KPIs
Medical Affairs KPIs
The purpose of this paper is to describe how effective Medical Affairs KPIs can be developed as straightforwardly as possible, and to present key elements that organisations should consider in their own KPI dashboards.